Long-term survival following additive radiotherapy in patients with atypical teratoid rhabdoid tumors

Khaled Elsayad(Goethe University Frankfurt), Hans Theodor Eich(University Hospital Münster), Jan Kříž(University Hospital Münster), Laith Samhouri(University Hospital Münster), Uwe Haverkamp(University Hospital Münster), Walter Stummer(University of Münster), Ronald Straeter(University Hospital Münster)

Strahlentherapie und Onkologie

June 7, 2016

10.1007/s00066-016-0978-8

Cited by 20

Related Papers

Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial

|The Lancet Oncology|2006|3.4k

EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME

|Neurosurgery|2008|1k

Fluorescence-guided resection of glioblastoma multiforme utilizing 5-ALA-induced porphyrins: a prospective study in 52 consecutive patients

|Journal of neurosurgery|2000|880

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial

|The Lancet|2019|581

What is the Surgical Benefit of Utilizing 5-Aminolevulinic Acid for Fluorescence-Guided Surgery of Malignant Gliomas?

|Neurosurgery|2015|368